July 20, 2010

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

.   .   

This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
See the associated editorial.

Related Articles:

Acute Kidney Injury, Vasculitis

Comments are closed.